RAD51 and neoplasm: Given the variety of necessary drug properties between diseases, we herein establish a versatile therapeutic approach that is potentially adaptable to multiple clinical oncology indications, balancing considerations such as nucleic acid release kinetics, RAD51 affinity, uptake kinetics, and tumor localization.